Clinical Oncology Next Generation Sequencing Market

Clinical Oncology Next-generation Sequencing Market: Launch of Low-cost Sequencing Platforms to Accelerate Adoption: Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2029

  • 2019-05-17
  • REP-GB-9543
  • 52 Tables
  • 109 Figures
  • 194 pages
  • PDF PPT EXCEL
 Clinical Oncology Next Generation Sequencing Market
  • SELECT LICENSE :

  • US$5,000
  • US$7,500
  • US$10,000

Clinical Oncology Next-Generation Sequencing – A method for cancer profiling

The demand of clinical oncology next-generation sequencing devices is expected to increase due to the increasing prevalence of cancer and rise in cancer diagnostics. The manufacturers of clinical oncology next-generation sequencing devices are majorly focusing on the partnerships and collaborations, especially international collaborations.

clinical oncology next generation sequencing market snapshot

Clinical Oncology Next-Generation Sequencing Market - Key Research Findings

  1. Global clinical oncology next-generation sequencing market size in 2018– Over US$ 200 Mn 

  1. The clinical oncology next-generation sequencing market is expected to observe a CAGR of 17.0% over 2019-2029. 

  1. North America and Europe are expected to remain the largest regional markets for clinical oncology next-generation sequencing 

  • The presence of well-established healthcare infrastructure in the U.S. is one of the major factors contributing to the growth of the clinical oncology next-generation sequencing market. 

  1. North America is expected to exhibit a high growth potential for the clinical oncology next-generation sequencing market 

  • Increasing healthcare awareness is expected to increase the boost the clinical oncology next-generation sequencing market. 

    clinical oncology next generation sequencing market

Top 3 Factors Shaping the Clinical Oncology Next-Generation Sequencing Market

  • Increasing prevalence of cancers

Increasing prevalence of cancer is a major factor responsible for the growth of the clinical oncology next-generation sequencing market. Increasing biomedical research using clinical oncology next-generation sequencing is expected to create a conducive atmosphere for the growth of the clinical oncology next-generation sequencing market in the near future. According to WHO, cancer is the second leading cause of death globally, and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths are caused by cancer. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths.

  • Increasing government funding for life science projects is expected to boost the clinical oncology next-generation sequencing market

Government funding for life science research is expected to result in the availability of funding for the undertaking of various clinical oncology next-generation sequencing projects, as well as for the employment of the required personnel. This is expected to contribute to the growth of the clinical oncology next-generation sequencing market.

The various sources of research and development spending include governments, private funding, and commercial organizations. Different life science projects have been undertaken, which has resulted in the employment of various personnel, and this is likely to fuel the growth of the clinical oncology next-generation sequencing market.

  • Declining prices of sequencing are highly likely to contribute to the growth of the clinical oncology next-generation sequencing market

The characteristic features of clinical oncology next-generation sequencing technology are implicated widely in research and academic institutes. Clinical oncology next-generation sequencing techniques offer a high percentage of reads and cost-effectiveness per read. This has been possible due to the launch of low-cost sequencing platforms in the market. This can increase the overall growth of the clinical oncology next-generation sequencing market. Various market players, such as Roche and Illumina, have introduced sequencing techniques that have reduced the cost of clinical oncology next-generation sequencing.

Clinical Oncology Next-Generation Sequencing Market Structure Analysis

  • In the global clinical oncology next-generation sequencing market, tier 1 companies hold a revenue share of more than 60%.

  • Most of the key players in the clinical oncology next-generation sequencing market focus on developing innovative products. They also focus on partnerships and collaborations to expand their product portfolio.

Market Set to Grow 4.9x between 2019 and 2029

The clinical oncology next-generation sequencing market is likely to witness steady growth over the course of the forecast period. Increasing prevalence of cancer, increasing government funding for life science projects and the declining prices of sequencing are some of the major factors driving the growth of the clinical oncology next-generation sequencing market.

Emerging Countries Promise New Growth Opportunities

North America is expected to contribute the highest revenue share in the global clinical oncology next-generation sequencing market in 2019. However, healthy growth is expected in developing countries, especially China, India, and South Korea. Among the emerging countries, China is likely to present sustained opportunities of growth for stakeholders in the clinical oncology next-generation sequencing market.

* This data is only a representation. Actual data may vary and will be available in report.

Emerging Countries Promise New Growth Opportunities
Emerging Countries Promise New Growth Opportunities
Emerging Countries Promise New Growth Opportunities
Emerging Countries Promise New Growth Opportunities
  • 2014
  • 2018
  • 2022
  • 2028
  • Arrow

The Broader Perspective

Stakeholders in the clinical oncology next-generation sequencing market are adopting new technologies for cancer profiling and molecular disgnostics. The key players of the clinical oncology next-generation sequencing market are mainly focusing on mergers and acquisitions, especially on international collaborations. This has helped developing countries provide support to establish centers of excellence. With public funding, equipment availability, and training, these collaborations are likely to be fruitful.

Sequencing Platforms – This segment is expected to witness a significant growth rate during the forecast period

Services – This segment is also expected to grow at a faster rate

Kits and Reagents – This segment has a large market share in the clinical oncology next-generation sequencing market

Synthesis Sequencing - This segment is expected to account for 70% of the total revenue in the overall market

Ion Semi-Conductor Sequencing– Ion semi-conductor holds a significant share in the overall market

Real-Time Sequencing – Real-time sequencing is expected to exhibit the fastest growth rate in the clinical oncology next-generation sequencing market

Targeted Tumour Genome Profiling – This segment holds a large market share in the clinical oncology next-generation sequencing market

Tumour Transcriptome Sequencing – Tumour transcriptome sequencing is expected to grow at the higher rate

Whole Tumour Exome Sequencing – This segment is expected to exhibit a large market share and a higher growth rate

Hospitals - Hospitals are expected to hold a large market share in the clinical oncology next-generation sequencing market

Clinical Research Organizations – Clinical research organisations hold 45% of the clinical oncology next-generation sequencing market

Diagnostic Laboratories – This segment is expected to witness growth during the forecast period

How Growth will Unfold

Sequencing Platforms | Services | Kits and Reagents

 Clinical Oncology Next Generation Sequencing Market  Clinical Oncology Next Generation Sequencing Market  Clinical Oncology Next Generation Sequencing Market

* This data is only a representation. Actual data may vary and will be available in report.

Click Here To Know How The Growth Will Unfold

Custom Market Research Services

FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Overview

Clinical oncology next generation sequencing Market: Global Industry Analysis 2014-2018 & Opportunity Assessment 2019-2029

A recent market study published by FMI “Clinical oncology next generation sequencing Market: Global Industry Analysis 2014-2018 & Forecast 2019-2029” offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as current growth parameters of the clinical oncology next generation sequencing market, the growth prospects of the market are obtained with maximum precision.

Clinical Oncology Next Generation Sequencing Market Taxonomy

The global clinical oncology next generation sequencing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Product

  • Sequencing Platforms
  • Sequencing Products
  • Kits and Reagents
  • Services

By Technology

  • Ion Semiconductor Sequencing
  • Pyro-Sequencing
  • Synthesis Sequencing (SBS)
  • Real Time Sequencing (SMRT)
  • Ligation Sequencing
  • Reversible Dye Termination Sequencing
  • Nano-Pore Sequencing

By Application

  • Whole Tumor Genome Sequencing
  • Whole Tumor Exome Sequencing
  • Targeted Tumor Genome Profiling
  • Tumor Transcriptome Sequencing
  • Tumor-normal Comparisons
  • Others

By End User

  • Hospital Laboratories
  • Clinical Research Organizations
  • Diagnostic Laboratories
  • Others

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

What's Included

The report commences with the executive summary of the clinical oncology next generation sequencing market, which includes a summary of the key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the clinical oncology next generation sequencing market.

Readers can find the detailed taxonomy and the definition of the Clinical oncology next generation sequencing market in this chapter, which will help them understand the basic information about the clinical oncology next generation sequencing market. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the clinical oncology next generation sequencing market report.

The report provides key market trends that are expected to impact the market growth significantly during the forecast period. Detailed industry trends are provided in this section, along with key market development or product innovations.

This section includes the key inclusions of the report. It includes product adoption & usage analysis, reimbursement scenario, pipeline assessment & opportunity analysis, and manufactures strategies for market expansion.

This section explain the global market value analysis and forecast for the clinical oncology next generation sequencing market between the forecast periods of 2014-2029 is highlights in this section. This chapter includes the detailed analysis of the historical clinical oncology next generation sequencing market, along with an opportunity analysis of the future. Readers can also find the absolute opportunity for the current year (2019 – 2020), and an incremental opportunity for the forecast period (2019 – 2029).

This section highlights the average price of clinical oncology next generation sequencing. The pricing benchmark for manufacturer level pricing and distributor level pricing is analysed in this section.

This section explain the global market volume analysis and forecast for the Clinical oncology next generation sequencing market between the forecast periods of 2019-2029 is highlights in this section.

This chapter explains the key macro-economic factors that are expected to influence the growth of the Clinical oncology next generation sequencing market over the forecast period. Along with macroeconomic factors, this section also highlights the opportunity analysis for the Clinical oncology next generation sequencing market. This chapter also highlights the key market dynamics of the clinical oncology next generation sequencing market, which include the drivers, restraints and trends. Moreover, readers will understand the key trends followed by the leading manufacturers in the clinical oncology next generation sequencing market.

Based on product type, the clinical oncology next generation sequencing market is segmented into sequencing Platforms, sequencing products, kits and reagents services.

In this chapter, readers can find information about the key trends and developments in the clinical oncology next generation sequencing market and market attractiveness analysis based on the product type.

This chapter provides details about the clinical oncology next generation sequencing market on the basis of technology, and has been classified into ion semiconductor sequencing, pyro-sequencing, synthesis sequencing (SBS), real time sequencing (SMRT), ligation sequencing, reversible dye termination sequencing and nano-pore sequencing. In this chapter, readers can understand the market attractive analysis based on disease indication.

This chapter provides details about the clinical oncology next generation sequencing market on the basis of application, and has been classified into whole tumor genome sequencing, whole tumor exome sequencing, targeted tumor genome profiling, tumor transcriptome sequencing, tumor-normal comparisons and others

In this chapter, readers can understand the market attractive analysis based on application.

This chapter provides details about the clinical oncology next generation sequencing market on the basis of end user, and has been classified into hospital laboratories, clinical research organizations, diagnostic laboratories and others. In this chapter, readers can understand the market attractive analysis based on end user.

This chapter explains how the clinical oncology next generation sequencing market will grow across various geographic regions, such as North America, Latin America, Europe, East Asia, South Asia, Oceania, the Middle East & Africa (MEA)

This chapter includes a detailed analysis of the growth of the North America clinical oncology next generation sequencing market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the regional trends, regulations, and market growth based on the end users and countries in North America.

Readers can find detailed information about several factors, such as the pricing analysis and the regional trends, which are impacting the growth of the Latin America clinical oncology next generation sequencing market. This chapter also includes the growth prospects of the clinical oncology next generation sequencing market in the leading LATAM countries such as Brazil, Mexico, Argentina, and the Rest of Latin America.

Important growth prospects of the clinical oncology next generation sequencing market based on its end users in several countries, such as Germany, the UK, France, Spain, Italy, Russia, and the Rest of Europe, are included in this chapter.

India, Indonesia, Thailand , Malaysia are the leading countries in the South Asia region that are the prime subjects of assessment to obtain the growth prospects of the South Asia clinical oncology next generation sequencing market in this chapter. Readers can find detailed information about the growth parameters of the South Asia clinical oncology next generation sequencing market during the period 2019-2029.

This chapter highlights the growth of the clinical oncology next generation sequencing market in the East Asia by focusing on China, Japan and South Korea. This section also helps readers understand the key factors that are responsible for the growth of the clinical oncology next generation sequencing market in East Asia.

In this chapter, Australia and New Zealand are among the leading countries in the Oceania region, which are the prime subjects of assessment to obtain the growth prospects of the Oceania clinical oncology next generation sequencing market.

This chapter provides information about how the clinical oncology next generation sequencing market will grow in the major countries in the MEA region, such as GCC Countries, South Africa, Turkey, Northern Africa and the rest of MEA, during the forecast period 2019 - 2029.

In this chapter, readers can find a detailed information about the tier analysis and market concentration of the key players in the clinical oncology next generation sequencing market along with their market presence analysis by region and product portfolio.

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the Clinical oncology next generation sequencing market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are  Illumina Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies, Ltd., Agilent Technologies, Inc., QIAGEN N.V., Takara Bio, Inc., and PerkinElmer Inc.  

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the clinical oncology next generation sequencing report.

This chapter helps readers understand the research methodology followed to obtain the various conclusions as well as important qualitative and quantitative information about the clinical oncology next generation sequencing market.

How the research was conducted?

Primary Research

Primary research interview with Key Opinion Leaders and other participants were conducted for data collection and validation of the below information:

  • Prevalence of Cancer
  • High Prevalence by Gender and Age-Group
  • Treatment Seeking Rate
  • Adoption of Clinical oncology next generation sequencing Devices as mode of treatment
  • Average Selling Price (US$) and Market Growth
  • Key Developments
  • Key Trends and Opportunities
  • Regional wise Dynamics
  • Reimbursement Landscape
  • Market Share Information
  • Key Brands
  • Competition & Key Vendor Strategies

Secondary Research

  • National Cancer Institute
  • Cancer Data and Statistics
  • National Health Portal of India
  • American Cancer Society
  • Indian Cancer Society
  • Canadian Cancer Society
  • Health Statistics and Data Management
  • Cancer Foundation of India
  • Chinese Anti-Cancer Association
  • European Organization of Research and Treatment of Cancer
  • Annual Reports/SEC filings/Investor Presentations/Earning Call Transcript
  • Industry Journals

Primary Interview Splits

Primary Research Interview Splits

Clinical Oncology Next Generation Sequencing Market Reports - Table of Contents

To Learn More About our Comprehensive Perspective on Clinical Oncology Next Generation Sequencing Market,

Get in touch

Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Client Partner - Global Business Development

* indicates mandatory fields

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Methodology